Ovid Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 8, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 8, 2024
OVID$2.80-1.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
Consolidated Statements of Cash Flows
| Year Ended December 31,2023 | Year Ended December 31,2022 | |
|---|---|---|
| Cash flows from operating activities: | ||
| Net loss | $(52,338,959) | $(54,169,029) |
| Adjustments to reconcile net loss to cash used in operating activities: | ||
| Non-cash consideration received in licensing agreement transaction | — | (945,366) |
| Unrealized (gain) loss on equity investments | (2,003,073) | 454,811 |
| Change in accrued interest income and accretion of discount on marketable securities | (2,172,254) | (1,211,311) |
| Stock-based compensation expense | 7,285,192 | 6,556,686 |
| Depreciation and amortization expense | 568,282 | 512,505 |
| Amortization of right-of-use asset | 1,028,293 | 869,100 |
| Change in lease liability | (533,946) | 936,927 |
| Change in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | (1,385,052) | 109,292 |
| Accounts payable | 1,750,026 | (5,174,136) |
| Accrued expenses | 2,020,566 | (3,166,606) |
| Net cash used in operating activities | (45,780,925) | (55,227,127) |
| Cash flows from investing activities: | ||
| Purchase of marketable securities | (112,443,150) | (172,964,441) |
| Sales/maturities of marketable securities | 120,000,000 | 90,000,000 |
| Purchase of long-term equity investments | (10,000,000) | (2,500,000) |
| Issuance of convertible short-term note receivable | — | (1,000,000) |
| Purchases of property and equipment | (40,308) | (1,224,379) |
| Software development and other costs | (97,147) | (194,397) |
| Net cash used in investing activities | (2,580,605) | (87,883,217) |
| Cash flows from financing activities: | ||
| Proceeds from exercise of options and employee stock purchase plan | 535,201 | 180,658 |
| Proceeds from royalty monetization agreement | 30,000,000 | — |
| Net cash provided by financing activities | 30,535,201 | 180,658 |
| Net decrease in cash, cash equivalents and restricted cash | (17,826,329) | (142,929,686) |
| Cash, cash equivalents and restricted cash, at beginning of period | 46,798,599 | 189,728,285 |
| Cash, cash equivalents and restricted cash, at end of period | $28,972,270 | $46,798,599 |
| Non-cash investing and financing activities: | ||
| Right-of-use asset in exchange for lease liability | $— | $15,791,769 |
| Conversion of short-term note receivable to long-term equity investment | $— | $1,000,000 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.